COVID-19
We recommend
Nirmatrelvir/ritonavir reduces the risk of hospitalization for COVID-19 even in the era of predominant omicron subvariants BA.4 and BA.5
One of the first studies to evaluate the efficacy of nirmatrelvir/ritonavir in non-hospitalized patients with COVID-19 infection during the period of predominant omicron variants including subvariants BA.4 and BA.5 has provided real-world data confirming the position of this antiviral in the first line of treatment for patients with mild to moderately severe SARS-CoV-2 infection and a high risk of severe disease.
No content is currently available on this topic.